The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.
Age 0.5-18 years (except neonates).
Pathologically confirmed medulloblastoma.
Not having received any other relevant treatment before surgery.
Completion of enhanced MRI of the head and spinal cord.
Patients who have recently received other drugs or radiation therapy.
Patients suffering from acute or chronic infectious diseases
Patients suffering from neurological or psychiatric diseases or mental disorders that cannot be easily controlled, or poor compliance.
Patients who cannot receive enhanced MRI scans.
350 medulloblastoma patients aged 0.5-18 years (except newborns)
Cohort
Prospective
Prospective observational study, no intervention
Other interventionProspective observational study, no intervention
Molecular typing
Medulloblastoma can be classified into four molecular types: WNT, SHH, G3 and G4.
Overall survival
the time from operation to death
Progression free survival
The time from operation to disease progression
Quality of life scale
A scale for evaluating the quality of life of patients after operation
Age at diagnosis
BMI
weight and height will be combined to report BMI in kg/m\^2
Click on the lead sponsor to view all of their trials.
Beijing Tiantan Hospital
Lead sponsor
Beijing Neurosurgical Institute
Collaborator
Beijing Children's Hospital
Collaborator
Beijing Shijitan Hospital, Capital Medical University
Collaborator
Xuanwu Hospital, Beijing
Collaborator
Peking University Third Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
